An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Trial Profile

An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Evofosfamide (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors EMD Serono
  • Most Recent Events

    • 29 Mar 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2016 according to the ClinicalTrials.gov records.
    • 29 Mar 2016 Status changed from recruiting to discontinued because of the sponsor decided to discontinue the development of Evofosfamide according to the ClinicalTrials.gov records.
    • 09 Nov 2015 Planned End Date changed from 1 Aug 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top